Pharmacokinetic Studies of an in Situ Forming Gel System for Controlled Delivery of Enrofloxacin in Pigs
Zugong Yu,Huimin Li,Zhang,Zhenrui Zhang,Jing Tian,Xiaoqing Luo
DOI: https://doi.org/10.15226/2374-6866/5/1/00149
2018-01-01
Abstract:article or s.c.(subcutaneous) injection [1,2,27,31,35]Thereby, the recommended dosing regimen of ENR conventional injection was administrated a single 2.5 ~ 5 mg/kg b.w. per day or twice a day, meaning that a course of treatment needs multiple dosing [40].Obviously, in the clinical application the conventional injection caused a lot of inconvenience, for example, repeated stress response maybe worsen animals' illness or result in more disease, and the drugs' action was not sufficient when it was in peaks and valleys, what's more, frequency administration spent great human, financial and material resources.On the other hand, studies revealed that the fluoroquinolones had biphasic concentration-dependent characteristics.When the blood drug concentrations were far more than the MIC (minimum inhibition concentration), they didn't have the killing effect, only had bacteriostatic action [4].Then the drugs' action could not be exerted sufficiently.It also brings new challenges to the development of long-acting injection of this drug.The preparation methods of traditional long-acting injection, such as the process for making suspension or oil, were to increase blood drug concentration by adding the dose, which maybe also play against the drug's efficacy.For these reasons, there is a need for at least drug administration as possible, followed by longer duration of therapeutically effective drug concentration in the body.Injectable in situ forming systems have received considerable interest over the past few years, which had many distinct advantages including simple operation, low cost, and easy industrialized production [8,20,21,24,30].The reversal thermal gelation (RTG) phenomenon constitutes one of the most promising strategies for the development of injectable drug delivery systems.The poloxamer 407 (P407) thermosensible in situ gels display low viscosity at ambient temperature, allowing the gel to flow freely into the body through a syringe during injection, and exhibit a sharp viscosity increase following a certain temperature rise, producing a semi-solid gel as the drug ' deposit ' at body temperature [25,33].Drugs release slow along with the gel to achieve the purpose of sustained-release.The in vitro process of thermo sensible in situ gel form of many drugs indicated that the release of this drug could sustain 4 ~ 7 days [23,28,29], which highly accorded with the medication cycle (3 ~ 5 days) in veterinary clinical application.